206 related articles for article (PubMed ID: 30838820)
21. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
[TBL] [Abstract][Full Text] [Related]
22. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
23. Surgery for lymph node metastases of medullary thyroid carcinoma: A review.
Jin LX; Moley JF
Cancer; 2016 Feb; 122(3):358-66. PubMed ID: 26539937
[TBL] [Abstract][Full Text] [Related]
24. Preoperative calcitonin testing improves the diagnosis of medullary thyroid carcinoma in female and male patients.
Weber T; Poplawski A; Vorländer C; Dotzenrath C; Ringelband R; Schabram J; Passler C; Zielke A; Schlegel N; Nies C; Krenz D; Jähne J; Schwab R; Bartsch DK; Binnebösel M; Kemen M; Klinger C; Buhr H; Lorenz K
Eur J Endocrinol; 2022 Jan; 186(2):223-231. PubMed ID: 34871180
[TBL] [Abstract][Full Text] [Related]
25. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986.
Girelli ME; Nacamulli D; Pelizzo MR; De Vido D; Mian C; Piccolo M; Busnardo B
Thyroid; 1998 Jun; 8(6):517-23. PubMed ID: 9669290
[TBL] [Abstract][Full Text] [Related]
26. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
27. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma.
Franc S; Niccoli-Sire P; Cohen R; Bardet S; Maes B; Murat A; Krivitzky A; Modigliani E;
Clin Endocrinol (Oxf); 2001 Sep; 55(3):403-9. PubMed ID: 11589685
[TBL] [Abstract][Full Text] [Related]
28. [Postoperative external beam radiotherapy for medullary thyroid carcinoma with high risk of locoregional relapse].
Compagnon F; Zerdoud S; Rives M; Laprie A; Sarini J; Grunenwald S; Chaltiel L; Graff P
Cancer Radiother; 2016 Jul; 20(5):362-9. PubMed ID: 27396902
[TBL] [Abstract][Full Text] [Related]
29. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
30. Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Arola J; Haglund C
Acta Oncol; 2016; 55(3):357-64. PubMed ID: 26339947
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous Deceleration and Acceleration of Growth Rate in Medullary Thyroid Carcinomas Suggested by Changes in Calcitonin Doubling Times Over Long-Term Surveillance.
Miyauchi A; Kudo T; Kihara M; Oda H; Ito Y; Miya A
World J Surg; 2019 Feb; 43(2):504-512. PubMed ID: 30229381
[TBL] [Abstract][Full Text] [Related]
32. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
Yeh T; Yeung M; Sherman EJ; Tuttle RM; Sabra MM
Thyroid; 2020 Aug; 30(8):1112-1119. PubMed ID: 32131709
[No Abstract] [Full Text] [Related]
33. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?
Niederle MB; Scheuba C; Riss P; Selberherr A; Koperek O; Niederle B
Thyroid; 2020 Jul; 30(7):974-984. PubMed ID: 32056502
[No Abstract] [Full Text] [Related]
34. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
35. Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study.
Twito O; Grozinsky-Glasberg S; Levy S; Bachar G; Gross DJ; Benbassat C; Rozental A; Hirsch D
Eur J Endocrinol; 2019 Jul; 181(1):13-21. PubMed ID: 31048559
[TBL] [Abstract][Full Text] [Related]
36. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
[TBL] [Abstract][Full Text] [Related]
37. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
38. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years.
Jung KY; Kim SM; Yoo WS; Kim BW; Lee YS; Kim KW; Lee KE; Jeong JJ; Nam KH; Lee SH; Hah JH; Chung WY; Yi KH; Park DJ; Youn YK; Sung MW; Cho BY; Park CS; Park YJ; Chang HS
Clin Endocrinol (Oxf); 2016 Apr; 84(4):587-97. PubMed ID: 26175307
[TBL] [Abstract][Full Text] [Related]
39. Different outcomes in sporadic versus familial medullary thyroid cancer.
Saltiki K; Simeakis G; Anagnostou E; Zapanti E; Anastasiou E; Alevizaki M
Head Neck; 2019 Jan; 41(1):154-161. PubMed ID: 30548085
[TBL] [Abstract][Full Text] [Related]
40. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
Kwon H; Kim WG; Jeon MJ; Song DE; Lee YM; Sung TY; Chung KW; Yoon JH; Hong SJ; Baek JH; Lee JH; Kim TY; Kim WB; Shong YK
Endocrine; 2016 Jul; 53(1):174-81. PubMed ID: 26754662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
